EUVIMEDEUVIMED entdecken
Crossref

FDA approves another OTC naloxone nasal spray

Alison Knopf

Alcoholism & Drug Abuse Weekly · 29.06.2026 · 38 (26) · 8-8

DOI: 10.1002/adaw.34967 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alcoholism & Drug Abuse Weekly, online erschienen am 02.07.2026. Verfasst von Alison Knopf.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The U.S. Food and Drug Administration (FDA) on June 16 approved another over‐the‐counter (OTC) intranasal naloxone product, Rextovy, a 4‐milligram naloxone hydrochloride nasal spray for the treatment of opioid overdose.

Zitieren

APA

Knopf, A. (2026). FDA approves another OTC naloxone nasal spray. Alcoholism & Drug Abuse Weekly, 38(26), 8-8. https://doi.org/10.1002/adaw.34967

Vancouver

Knopf A. FDA approves another OTC naloxone nasal spray. Alcoholism & Drug Abuse Weekly. 2026;38(26):8-8. doi:10.1002/adaw.34967

BibTeX
@article{Knopf2026,
  author = {Knopf, Alison},
  title = {FDA approves another OTC naloxone nasal spray},
  journal = {Alcoholism & Drug Abuse Weekly},
  year = {2026},
  volume = {38},
  number = {26},
  pages = {8--8},
  doi = {10.1002/adaw.34967}
}
Kostenlos starten →